Hyaluronidase NDC 51662-1555

NDC codes

FDA NDC Directory

Product NDC (as listed)51662-1555Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51662-1555Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51662-1555-1	51662155501	1 VIAL in 1 BOX (51662-1555-1) / 1 mL in 1 VIALMarketed from Jun 4, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Hyaluronidase
Generic name (nonproprietary): hyaluronidase
Active ingredients: Hyaluronidase (Human recombinant) — 150 [USP'U]/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: HF Acquisition Co LLC, DBA HealthFirst
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 021859
Marketing start: Jun 4, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Glycoside Hydrolases (Chemical structure)
Identifiers: Product ID 51662-1555_c3f1db01-58c0-2226-e053-2a95a90a8b33SPL ID c3f1db01-58c0-2226-e053-2a95a90a8b33SPL set ID c3f1db01-58bf-2226-e053-2a95a90a8b33RxCUI 630936, 630939UNII 743QUY4VD8
Pharmacologic class: Endoglycosidase

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451662155501 followed by a unit qualifier and the quantity

Package 51662-1555-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 4, 2021.

Indications (excerpt from the label)

1.1 Subcutaneous Fluid Administration HYLENEX recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. 1.2 Dispersion and Absorption of Injected Drugs HYLENEX recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. 1.3 Subcutaneous Urography HYLENEX recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 021859

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 021859
Product	Strength	Form · route	Labeler	Product NDC
HYLENEX Recombinanthyaluronidase	Hyaluronidase (Human recombinant) 150 [USP'U]/mL	Injection, SolutionSubcutaneous	Antares Pharma, Inc.	18657-117